News Archive
For patients diagnosed with skin cancer, particularly basal cell and squamous cell carcinoma, one of the best treatment options can be Mohs surgery, a tissue-sparing, tumor-removal procedure.
GW Radiation Oncology is pleased to share the 2021 Annual Report, a summary of our efforts to adapt to the COVID-19 pandemic, address health disparities, and improve diversity and inclusion.
Prostate cancer is one of the most common cancers, making Prostate Cancer Awareness Month, recognized every September, a good reminder for men to stay
September is Ovarian Cancer Awareness Month, a timely reminder for women, particularly those age 60 and older, to take stock of their health. Ovarian cancer, according to the American Cancer Society (ACS), is the deadliest of all female reproductive cancers and ranks fifth in cancer deaths among…
Vishal Patel, MD, director of the Cutaneous Oncology Program at the GW Cancer Center and the GW Medical Faculty Associates, breaks down what you need to know about skin cancer, how it is treated, and what you can do to protect yourself now.
Colorectal cancer is the third leading cause for cancer related deaths in the United States, and March is Colorectal Cancer Awareness Month.
In 2017, Antoinette Brosset tackled breast cancer with specialized care from her medical team at the George Washington University (GW) Hospital Cancer Center. When cancer "knocked on her door a second time" in 2018 with a colorectal cancer diagnosis, her GW team was there for her again, every…
George Washington University (GW) has entered a new $3.2 million corporate research agreement with US Patent Innovations, LLC (USPI) to support further development of adaptive cold plasma devices for cancer therapies and explore using these devices to combat the spread of COVID-19.
Four young researchers at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) were selected as fellows to the recently awarded five-year National Cancer Institute T32 Training Grant.
WASHINGTON (Sept. 9, 2020) - Spironolactone is not associated with increased risk of female breast cancer recurrence, according to research from the George Washington University (GW) Department of Dermatology.